BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3102088)

  • 1. Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
    Wiltshaw E; Westbury G; Harmer C; McKinna A; Fisher C
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S10-2. PubMed ID: 3102088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
    Huang YH; Wen XP; Hu L
    Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide combination regimens for soft-tissue sarcoma.
    Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
    Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
    Schütte J; Mouridsen HT; Stewart W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
    Eur J Cancer; 1990; 26(5):558-61. PubMed ID: 2144740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J; Kellner R; Seeber S
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
    Cantwell BM; Carmichael J; Ghani S; Harris AL
    Cancer Chemother Pharmacol; 1988; 21(1):49-52. PubMed ID: 3124971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
    Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
    Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
    Wiklund TA; Blomqvist CP; Virolainen M; Elomaa I
    Cancer Chemother Pharmacol; 1992; 30(2):100-4. PubMed ID: 1600589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
    Toma S; Coialbu T; Biassoni L; Folco U; Gatti C; Canavese G; Giacchero A; Rosso R
    Cancer Chemother Pharmacol; 1990; 26(6):453-6. PubMed ID: 2121378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
    Weh HJ; Zügel M; Wingberg D; Schwarz R; Zornig C; Dietel M; Hossfeld DK
    Onkologie; 1990 Dec; 13(6):448-52. PubMed ID: 2128712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
    J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
    Antman KH; Montella D; Rosenbaum C; Schwen M
    Cancer Treat Rep; 1985 May; 69(5):499-504. PubMed ID: 3924401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
    Skubitz KM; Hamdan H; Thompson RC
    Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
    Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
    Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
    Schütte J; Mouridsen HT; Steward W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S204-9. PubMed ID: 8453699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
    J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
    Falkson G; Chasen MR; Falkson HC
    Invest New Drugs; 1990 May; 8(2):215-9. PubMed ID: 2166721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.